Microbiota and Diabetes Mellitus: Role of Lipid Mediators
Diabetes Mellitus (DM) is an inflammatory clinical entity with different mechanisms involved in its physiopathology. Among these, the dysfunction of the gut microbiota stands out. Currently, it is understood that lipid products derived from the gut microbiota are capable of interacting with cells fr...
- Autores:
-
Salazar, Juan
Angarita, Lissé
Morillo, Valery
Navarro, Carla
Martínez, María Sofía
Chacín, Maricarmen
Torres, Wheeler
Rajotia, Arush
Rojas, Milagros
Cano, Clímaco
Añez, Roberto
Rojas, Joselyn
Bermúdez, Valmore
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/7003
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/7003
https://doi.org/10.3390/nu12103039
https://www.mdpi.com/2072-6643/12/10/3039
- Palabra clave:
- Diabetes
Inflammation
Microbiota
Dysbiosis
Lipopolysaccharides
Short-chain
Fatty acids
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
| id |
USIMONBOL2_9e7902dc574633219602e9a1d78b97ee |
|---|---|
| oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/7003 |
| network_acronym_str |
USIMONBOL2 |
| network_name_str |
Repositorio Digital USB |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators |
| title |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators |
| spellingShingle |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators Diabetes Inflammation Microbiota Dysbiosis Lipopolysaccharides Short-chain Fatty acids |
| title_short |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators |
| title_full |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators |
| title_fullStr |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators |
| title_full_unstemmed |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators |
| title_sort |
Microbiota and Diabetes Mellitus: Role of Lipid Mediators |
| dc.creator.fl_str_mv |
Salazar, Juan Angarita, Lissé Morillo, Valery Navarro, Carla Martínez, María Sofía Chacín, Maricarmen Torres, Wheeler Rajotia, Arush Rojas, Milagros Cano, Clímaco Añez, Roberto Rojas, Joselyn Bermúdez, Valmore |
| dc.contributor.author.none.fl_str_mv |
Salazar, Juan Angarita, Lissé Morillo, Valery Navarro, Carla Martínez, María Sofía Chacín, Maricarmen Torres, Wheeler Rajotia, Arush Rojas, Milagros Cano, Clímaco Añez, Roberto Rojas, Joselyn Bermúdez, Valmore |
| dc.subject.spa.fl_str_mv |
Diabetes |
| topic |
Diabetes Inflammation Microbiota Dysbiosis Lipopolysaccharides Short-chain Fatty acids |
| dc.subject.eng.fl_str_mv |
Inflammation Microbiota Dysbiosis Lipopolysaccharides Short-chain Fatty acids |
| description |
Diabetes Mellitus (DM) is an inflammatory clinical entity with different mechanisms involved in its physiopathology. Among these, the dysfunction of the gut microbiota stands out. Currently, it is understood that lipid products derived from the gut microbiota are capable of interacting with cells from the immune system and have an immunomodulatory effect. In the presence of dysbiosis, the concentration of lipopolysaccharides (LPS) increases, favoring damage to the intestinal barrier. Furthermore, a pro-inflammatory environment prevails, and a state of insulin resistance and hyperglycemia is present. Conversely, during eubiosis, the production of short-chain fatty acids (SCFA) is fundamental for the maintenance of the integrity of the intestinal barrier as well as for immunogenic tolerance and appetite/satiety perception, leading to a protective effect. Additionally, it has been demonstrated that alterations or dysregulation of the gut microbiota can be reversed by modifying the eating habits of the patients or with the administration of prebiotics, probiotics, and symbiotics. Similarly, different studies have demonstrated that drugs like Metformin are capable of modifying the composition of the gut microbiota, promoting changes in the biosynthesis of LPS, and the metabolism of SCFA. |
| publishDate |
2020 |
| dc.date.issued.none.fl_str_mv |
2020 |
| dc.date.accessioned.none.fl_str_mv |
2021-01-20T23:07:35Z |
| dc.date.available.none.fl_str_mv |
2021-01-20T23:07:35Z |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.driver.eng.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.spa.spa.fl_str_mv |
Artículo científico |
| dc.identifier.issn.none.fl_str_mv |
20726643 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/7003 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3390/nu12103039 |
| dc.identifier.url.none.fl_str_mv |
https://www.mdpi.com/2072-6643/12/10/3039 |
| identifier_str_mv |
20726643 |
| url |
https://hdl.handle.net/20.500.12442/7003 https://doi.org/10.3390/nu12103039 https://www.mdpi.com/2072-6643/12/10/3039 |
| dc.language.iso.eng.fl_str_mv |
eng |
| language |
eng |
| dc.rights.*.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.eng.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.eng.fl_str_mv |
Nutrients |
| dc.source.none.fl_str_mv |
Vol. 12, No. 10, 2020 |
| institution |
Universidad Simón Bolívar |
| bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/ae3e9a76-f10f-4c99-aa8e-76fbf1a9efc5/download https://bonga.unisimon.edu.co/bitstreams/949d02f8-57bb-472a-acf7-b2bf4a3f3649/download https://bonga.unisimon.edu.co/bitstreams/949e5701-d0c7-478f-ab64-79723322e1a2/download https://bonga.unisimon.edu.co/bitstreams/f54f0da2-588a-4e67-ab16-a4e1b93b3579/download https://bonga.unisimon.edu.co/bitstreams/c74ba7fc-160e-4324-ab12-464860b0906a/download https://bonga.unisimon.edu.co/bitstreams/0dde2498-e38f-4976-8fd1-2caf4ec638e6/download https://bonga.unisimon.edu.co/bitstreams/41a55f46-e53d-433b-a93a-5a6286e3ae16/download |
| bitstream.checksum.fl_str_mv |
1de51755447e8f231fc7158108f84bb8 4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 54cc2d13a02f199db14efea76b3d10fb b6458a6972d91144fe1004934b1f3381 21a04d2bd9aa4a8a41c188fff68f3e13 97e47bfe5014a0ab6a7ad96f39202e30 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
| repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
| _version_ |
1814076028748824576 |
| spelling |
Salazar, Juan1be82f2b-2e1c-497f-b8c3-789a462fc4f2Angarita, Lissécd37d36e-0d41-457f-9dc8-1ed5b9201b16Morillo, Valeryf3f6dd3c-b192-4bf7-83c7-b7b1400b56b3Navarro, Carlae0012636-ad49-43ac-b575-384725db4facMartínez, María Sofía0dda0581-5723-45c7-baaa-ff01d6379071Chacín, Maricarmenfdb0f1d1-c963-4360-8d3b-f21d402ee436Torres, Wheeler8bebaba2-fe5b-4212-8990-49506592a59eRajotia, Arush7b711d22-c609-42bf-9f22-785c8079195cRojas, Milagros3283fd88-1355-4c19-9a5a-47a9e268ad27Cano, Clímacob7d55d6b-f1bf-4136-9b90-54a80ab90ab2Añez, Roberto233a8885-3f6a-4c67-ab42-f44cd09e3b3fRojas, Joselyn07d42fd8-6b58-4bbf-96e1-fc1f43eee7dbBermúdez, Valmore41d9bc65-14f2-4c9e-9590-5f977e2d60a92021-01-20T23:07:35Z2021-01-20T23:07:35Z202020726643https://hdl.handle.net/20.500.12442/7003https://doi.org/10.3390/nu12103039https://www.mdpi.com/2072-6643/12/10/3039Diabetes Mellitus (DM) is an inflammatory clinical entity with different mechanisms involved in its physiopathology. Among these, the dysfunction of the gut microbiota stands out. Currently, it is understood that lipid products derived from the gut microbiota are capable of interacting with cells from the immune system and have an immunomodulatory effect. In the presence of dysbiosis, the concentration of lipopolysaccharides (LPS) increases, favoring damage to the intestinal barrier. Furthermore, a pro-inflammatory environment prevails, and a state of insulin resistance and hyperglycemia is present. Conversely, during eubiosis, the production of short-chain fatty acids (SCFA) is fundamental for the maintenance of the integrity of the intestinal barrier as well as for immunogenic tolerance and appetite/satiety perception, leading to a protective effect. Additionally, it has been demonstrated that alterations or dysregulation of the gut microbiota can be reversed by modifying the eating habits of the patients or with the administration of prebiotics, probiotics, and symbiotics. Similarly, different studies have demonstrated that drugs like Metformin are capable of modifying the composition of the gut microbiota, promoting changes in the biosynthesis of LPS, and the metabolism of SCFA.pdfengMDPIAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2NutrientsVol. 12, No. 10, 2020DiabetesInflammationMicrobiotaDysbiosisLipopolysaccharidesShort-chainFatty acidsMicrobiota and Diabetes Mellitus: Role of Lipid Mediatorsinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1International Diabetes Federation. IDF Diabetes Atlas. 2015. Available online: https://www.idf.org/elibrary/ epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html (accessed on 20 March 2020).De La Cruz Vargas, J.A.; Dos Santos, F.; Dyzinger, W.; Herzog, S. Medicina Del Estilo de Vida: Trabajando Juntos Para Revertir La Epidemia de Las Enfermedades Crónicas En Latinoamérica. Cienc. Innov. Salud 2017, 4. [CrossRef]Baratieri, T.; Dal Santo Ottoni, J.; Luciana Botti, M.; Serpa Maicel, R.D.C.; Gramazio Soares, L. Risco Cardiovascular Em Usuários de Programa de Atenção a Hipertensos e Diabéticos Em Um Município Do Paraná-Brasil. Cienc. Innov. Salud 2014, 2. [CrossRef]Morales, J.; Carcausto, W.; Varillas, Y.; Pérez, J.; Salsavilca, E.; Castro, I.; Rivera, M.; Quispe, M. Actividad Física En Pacientes Con Diabetes Mellitus Del Primer Nivel de Atención de Lima Norte. Rev. Latinoam. Hipertens. 2018, 13, 49–54Gonzalez, C.M.C.; Quiroz, E.A.N.; Lastre-Amell, G.; Oróstegui-Santander, M.A.; Peña, G.E.G.; Sucerquia, A.; Carrero, L.L.S. Dislipidemia como factor de riesgo cardiovascular: Uso de probióticos en la terapéutica nutricional. Arch. Venez. Farmacol. Ter. 2020, 39, 126–139.Rodríguez Nieves, R.R.; Torres Ruiz, L.E.; Sarmiento Segarra, K.B.; Narea Illescas, D.I.; Araque Pluas, I.V.; Apolo Montero, A.M.; Ibarra Vélez, L.S.; Alvarado Chiquito, O.L. Prevalencia de Síndrome Metabólico En Trabajadores de Una Empresa de Construcción En Guayaquil, Ecuador. Rev. Latinoam. Hipertens. 2019, 14, 638–643.Zozulinska, D.; Wierusz-Wysocka, B. Type 2 Diabetes Mellitus as Inflammatory Disease. Diabetes Res. Clin. Pract. 2006, 74, S12–S16. [CrossRef]Román-Pintos, L.M.; Villegas-Rivera, G.; Rodríguez-Carrizalez, A.D.; Miranda-Díaz, A.G.; Cardona-Muñoz, E.G. Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. J. Diabetes Res. 2016, 2016, 3425617. [CrossRef]Romero, G. Influencia de La Microbiota Intestinal En La Enfermedad Hepática Crónica. Su Rol En El Hepatocarcinoma. Gen 2016, 70, 64–69Vargas-Robles, D.D.; Domínguez-Bello, M.G. Microbiota de los indígenas del Amazonas venezolano: Influencia de los estilos de vida. Gac. Med. Caracas 2020, 126, 291–303.Torres, Y.; Bermúdez, V.; Garicano, C.; Vilasmil, N.; Bautista, J.; Martínez, M.S.; Rojas-Quintero, J. Desarrollo del sistema inmunológico ¿naturaleza o crianza? Arch. Venez. Farmacol. Ter. 2017, 36, 144–151.Faneite Antique, D.P.; Faneite Campos, J. Microbioma perinatal: Nuevos horizontes de la vida. Gac. Med. Caracas 2020, 123, 94–106Ruiz, L.; Delgado, S.; Ruas-Madiedo, P.; Sánchez, B.; Margolles, A. Bifidobacteria and Their Molecular Communication with the Immune System. Front. Microbiol. 2017, 8, 2345. [CrossRef]García, P.O. La fibra alimentaria y su uso terapéutico en algunas enfermedades crónicas. Gac. Med. Caracas 2020, 120, 107–114.Dávila, L.A.; Pirela, V.B.; Díaz, W.; Villasmil, N.R.; León, S.C.; Contreras, M.C.E.; Bonacich, K.B.; Agüero, S.D.; Vergara, P.C.; Bonacich, R.B.; et al. The Microbiome and the Epigenetics of Diabetes Mellitus. In Diabetes Food Plan; Waisundara, V., Ed.; InTech: London, UK, 2018.Carpio Duran, A.L.; Duran Medina, M.F.; Andrade Valdivieso, M.R.; Espinoza Dunn, M.A.; Rodas Torres, W.P.; Abad Barrera, L.N.; Rodríguez Barzola, C.V.; Yagual Villon, O.A. Terapia Incretinomimética: Evidencia Clínica de La Eficacia de Los Agonistas Del GLP-1R y Sus Efectos Cardio-Protectores. Rev. Latinoam. Hipertens. 2018, 13, 400–415Dávila, L.A.; Pirela, V.B.; Villasmil, N.R.; Cisternas, S.; Díaz, W.; Escobar, M.C.; Carrasco, P.; Durán, S.; Buhring, K.; Buhring, R.; et al. New Insights into Alleviating Diabetes Mellitus: Role of Gut Microbiota and a Nutrigenomic Approac. In Diabetes Food Plan; Waisundara, V., Ed.; InTech: London, UK, 2018.Bolívar González, S.; Talero Barrientos, E.; Motilva Sánchez, V. Efectos de Un Preparado Probiótico En Un Modelo de Colitis Experimental Crónica En Ratones, Inducida Por La Ingesta de Dextrano Sulfato Sódico (DSS). Cienc. Innov. Salud 2015, 3. [CrossRef]Bonora, E.; Cigolini, M.; Bosello, O.; Zancanaro, C.; Capretti, L.; Zavaroni, I.; Coscelli, C.; Butturini, U. Lack of Effect of Intravenous Metformin on Plasma Concentrations of Glucose, Insulin, C-Peptide, Glucagon and Growth Hormone in Non-Diabetic Subjects. Curr. Med. Res. Opin. 1984, 9, 47–51. [CrossRef]Moreira, G.V.; Azevedo, F.F.; Ribeiro, L.M.; Santos, A.; Guadagnini, D.; Gama, P.; Liberti, E.A.; Saad, M.; Carvalho, C. Liraglutide Modulates Gut Microbiota and Reduces NAFLD in Obese Mice. J. Nutr. Biochem. 2018, 62, 143–154. [CrossRef]Ministery of Health. Bolivarian Republic of Venezuela. Anuary of Morbility. 2011. Available online: https: //www.ovsalud.org/descargas/publicaciones/documentos-oficiales/Anuario-Morbilidad-2011.pdf (accessed on 20 March 2020).World Health Organization. Global Report on Diabetes; World Health Organization: Geneva, Switzerland, 2016. Available online: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf (accessed on 20 March 2020).De Fronzo, R.A. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 2009, 58, 773–795. [CrossRef] [PubMed]Schwartz, S.S.; Epstein, S.; Corkey, B.E.; Grant, S.F.A.; Gavin, J.R.; Aguilar, R.B. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care 2016, 39, 179–186. [CrossRefVatanen, T.; Kostic, A.D.; D’Hennezel, E.; Siljander, H.; Franzosa, E.A.; Yassour, M.; Kolde, R.; Vlamakis, H.; Arthur, T.D.; Hämäläinen, A.-M.; et al. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell 2016, 165, 842–853. [CrossRef]Brown, K.; Godovannyi, A.; Ma, C.; Zhang, Y.; Ahmadi-Vand, Z.; Dai, C.; Gorzelak, M.A.; Chan, Y.; Chan, J.M.; Lochner, A.; et al. Prolonged Antibiotic Treatment Induces a Diabetogenic Intestinal Microbiome That Accelerates Diabetes in NOD Mice. ISME J. 2016, 10, 321–332. [CrossRef]Palacios, T.; Vitetta, L.; Coulson, S.; Madigan, C.D.; Denyer, G.S.; Caterson, I.D. The Effect of a Novel Probiotic on Metabolic Biomarkers in Adults with Prediabetes and Recently Diagnosed Type 2 Diabetes Mellitus: Study Protocol for a Randomized Controlled Trial. Trials 2017, 18. [CrossRef]Peng, J.; Narasimhan, S.; Marchesi, J.R.; Benson, A.; Wong, F.S.; Wen, L. Long Term Effect of Gut Microbiota Transfer on Diabetes Development. J. Autoimmun. 2014, 53, 85–94. [CrossRef]Herder, C.; Færch, K.; Carstensen-Kirberg, M.; Lowe, G.D.; Haapakoski, R.; Witte, D.R.; Brunner, E.J.; Roden, M.; Tabák, A.G.; Kivimäki, M.; et al. Biomarkers of Subclinical Inflammation and Increases in Glycaemia, Insulin Resistance and Beta-Cell Function in Non-Diabetic Individuals: The Whitehall II Study. Eur. J. Endocrinol. 2016, 175, 367–377. [CrossRef] [PubMed]Pouvreau, C.; Dayre, A.; Butkowski, E.G.; de Jong, B.; Jelinek, H.F. Inflammation and Oxidative Stress Markers in Diabetes and Hypertension. J. Inflamm. Res. 2018, 11, 61–68. [CrossRef] [PubMed]Odegaard, A.O.; Jacobs, D.R.; Sanchez, O.A.; Goff, D.C.; Reiner, A.P.; Gross, M.D. Oxidative Stress, Inflammation, Endothelial Dysfunction and Incidence of Type 2 Diabetes. Cardiovasc. Diabetol. 2016, 15, 51. [CrossRef] [PubMed]Bermudez, V.; Salazar, J.; Gonzalez, R.; Ortega, A.; Calvo, M.; Olivar, L.C.; Morillo, J.; Miquilena, E.; Chavez-Castillo, M.; Chaparro, R.; et al. Prevalence and Risk Factors Associated with Impaired Fasting Glucose in Adults from Maracaibo City, Venezuela. J. Diabetes Metab. 2019, 7, 100683. [CrossRef]Rojas, J.; Bermudez, V.; Palmar, J.; Martínez, M.S.; Olivar, L.C.; Nava, M.; Tomey, D.; Rojas, M.; Salazar, J.; Garicano, C.; et al. Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes Therapy. J. Diabetes Res. 2018, 2018, 9601801. [CrossRef]Mobini, R.; Tremaroli, V.; Ståhlman, M.; Karlsson, F.; Levin, M.; Ljungberg, M.; Sohlin, M.; Bertéus Forslund, H.; Perkins, R.; Bäckhed, F.; et al. Metabolic Effects of Lactobacillus Reuteri DSM 17938 in People with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Obes. Metab. 2017, 19, 579–589. [CrossRef] [PubMed]Ahmad, R.; Thomas, R.; Kochumon, S.; Sindhu, S. Increased Adipose Tissue Expression of IL-18R and Its Ligand IL-18 Associates with Inflammation and Insulin Resistance in Obesity. Immun. Inflamm. Dis. 2017, 5, 318–335. [CrossRef]Yan, Y.; Li, S.; Liu, Y.; Bazzano, L.; He, J.; Mi, J.; Chen, W. Temporal Relationship between Inflammation and Insulin Resistance and Their Joint Effect on Hyperglycemia: The Bogalusa Heart Study. Cardiovasc. Diabetol. 2019, 18, 109. [CrossRef]Esser, N.; Legrand-Poels, S.; Piette, J.; Scheen, A.J.; Paquot, N. Inflammation as a Link between Obesity, Metabolic Syndrome and Type 2 Diabetes. Diabetes Res. Clin. Pract. 2014, 105, 141–150. [CrossRef]Roohi, A.; Tabrizi, M.; Abbasi, F.; Ataie-Jafari, A.; Nikbin, B.; Larijani, B.; Qorbani, M.; Meysamie, A.; Asgarian-Omran, H.; Nikmanesh, B.; et al. Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls. Biomed. Res. Int. 2014, 2014, 718946. [CrossRef] [PubMed]Abdel-Moneim, A.; Bakery, H.H.; Allam, G. The Potential Pathogenic Role of IL-17/Th17 Cells in Both Type 1 and Type 2 Diabetes Mellitus. Biomed. Pharmacother. 2018, 101, 287–292. [CrossRef] [PubMed]Von Scholten, B.J.; Reinhard, H.; Hansen, T.W.; Schalkwijk, C.G.; Stehouwer, C.; Parving, H.-H.; Jacobsen, P.K.; Rossing, P. Markers of Inflammation and Endothelial Dysfunction Are Associated with Incident Cardiovascular Disease, All-Cause Mortality, and Progression of Coronary Calcification in Type 2 Diabetic Patients with Microalbuminuria. J. Diabetes Complicat. 2016, 30, 248–255. [CrossRef]Sigurdardottir, S.; Zapadka, T.E.; Lindstrom, S.I.; Liu, H.; Taylor, B.E.; Lee, C.A.; Kern, T.S.; Taylor, P.R. Diabetes-Mediated IL-17A Enhances Retinal Inflammation, Oxidative Stress, and Vascular Permeability. Cell. Immunol. 2019, 341, 103921. [CrossRef]Burcelin, R. Gut Microbiota and Immune Crosstalk in Metabolic Disease. Mol. Metab. 2016, 5, 771–781. [CrossRef]Huang, X.; Yan, D.; Xu, M.; Li, F.; Ren, M.; Zhang, J.; Wu, M. Interactive Association of Lipopolysaccharide and Free Fatty Acid with the Prevalence of Type 2 Diabetes: A Community-Based Cross-Sectional Study. J. Diabetes Investig. 2019, 10, 1438–1446. [CrossRef]Khondkaryan, L.; Margaryan, S.; Poghosyan, D.; Manukyan, G. Impaired Inflammatory Response to LPS in Type 2 Diabetes Mellitus. Int. J. Inflam. 2018, 2018, 2157434. [CrossRef]Zhao, L.; Zhang, F.; Ding, X.; Wu, G.; Lam, Y.Y.; Wang, X.; Fu, H.; Xue, X.; Lu, C.; Ma, J.; et al. Gut Bacteria Selectively Promoted by Dietary Fibers Alleviate Type 2 Diabetes. Science 2018, 359, 1151–1156. [CrossRef]Li, M.; van Esch, B.C.A.M.; Wagenaar, G.T.M.; Garssen, J.; Folkerts, G.; Henricks, P.A.J. Pro- and Anti-Inflammatory Effects of Short Chain Fatty Acids on Immune and Endothelial Cells. Eur. J. Pharmacol. 2018, 831, 52–59. [CrossRef] [PubMed]Turnbaugh, P.J.; Ley, R.E.; Hamady, M.; Fraser-Liggett, C.M.; Knight, R.; Gordon, J.I. The Human Microbiome Project. Nature 2007, 449, 804–810. [CrossRef] [PubMed]Martí, J.M.; Martínez-Martínez, D.; Rubio, T.; Gracia, C.; Peña, M.; Latorre, A.; Moya, A.; Garay, C.P. Health and Disease Imprinted in the Time Variability of the Human Microbiome. MSystems 2017, 2. [CrossRef] [PubMed]Hill, C.J.; Lynch, D.B.; Murphy, K.; Ulaszewska, M.; Jeffery, I.B.; O’Shea, C.A.; Watkins, C.; Dempsey, E.; Mattivi, F.; Tuohy, K.; et al. Evolution of Gut Microbiota Composition from Birth to 24 Weeks in the INFANTMET Cohort. Microbiome 2017, 5, 4. [CrossRef]Duranti, S.; Lugli, G.A.; Milani, C.; James, K.; Mancabelli, L.; Turroni, F.; Alessandri, G.; Mangifesta, M.; Mancino, W.; Ossiprandi, M.C.; et al. Bifidobacterium bifidum and the infant gut microbiota: An intriguing case of microbe-host co-evolution. Environ. Microbiol. 2019, 21, 3683–3695. [CrossRef]Biagi, E.; Nylund, L.; Candela, M.; Ostan, R.; Bucci, L.; Pini, E.; Nikkïla, J.; Monti, D.; Satokari, R.; Franceschi, C.; et al. Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians. PLoS ONE 2010, 5, e10667. [CrossRef]Jeffery, I.B.; Lynch, D.B.; O’Toole, P.W. Composition and Temporal Stability of the Gut Microbiota in Older Persons. ISME J. 2016, 10, 170–182. [CrossRef] [PubMed]Alkanani, A.K.; Hara, N.; Gottlieb, P.A.; Ir, D.; Robertson, C.E.; Wagner, B.D.; Frank, D.N.; Zipris, D. Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes. Diabetes 2015, 64, 3510–3520. [CrossRef] [PubMed]Clarke, S.F.; Murphy, E.F.; O’Sullivan, O.; Lucey, A.J.; Humphreys, M.; Hogan, A.; Hayes, P.; O’Reilly, M.; Jeffery, I.B.; Wood-Martin, R.; et al. Exercise and Associated Dietary Extremes Impact on Gut Microbial Diversity. Gut 2014, 63, 1913–1920. [CrossRef] [PubMed]Carding, S.; Verbeke, K.; Vipond, D.T.; Corfe, B.M.; Owen, L.J. Dysbiosis of the Gut Microbiota in Disease. Microb. Ecol. Health Dis. 2015, 26. [CrossRef] [PubMed]Pomié, C.; Blasco-Baque, V.; Klopp, P.; Nicolas, S.; Waget, A.; Loubières, P.; Azalbert, V.; Puel, A.; Lopez, F.; Dray, C.; et al. Triggering the Adaptive Immune System with Commensal Gut Bacteria Protects against Insulin Resistance and Dysglycemia. Mol. Metab. 2016, 5, 392–403. [CrossRef] [PubMedMorales, P.; Fujio, S.; Navarrete, P.; Ugalde, J.A.; Magne, F.; Carrasco-Pozo, C.; Tralma, K.; Quezada, M.; Hurtado, C.; Covarrubias, N.; et al. Impact of Dietary Lipids on Colonic Function and Microbiota: An Experimental Approach Involving Orlistat-Induced Fat Malabsorption in Human Volunteers. Clin. Transl. Gastroenterol. 2016, 7, e161. [CrossRef]Endesfelder, D.; Zu Castell, W.; Ardissone, A.; Davis-Richardson, A.G.; Achenbach, P.; Hagen, M.; Pflueger, M.; Gano, K.A.; Fagen, J.R.; Drew, J.C.; et al. Compromised Gut Microbiota Networks in Children with Anti-Islet Cell Autoimmunity. Diabetes 2014, 63, 2006–2014. [CrossRef]Ghosh, S.S.; Wang, J.; Yannie, P.; Ghosh, S. Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development. J. Endocr. Soc. 2020, 4, bvz039. [CrossRef]Cani, P.D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A.M.; Delzenne, N.M.; Burcelin, R. Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice. Diabetes 2008, 57, 1470–1481. [CrossRef]Cani, P.D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A.M.; Delzenne, N.M.; Burcelin, R. Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice. Diabetes 2008, 57, 1470–1481. [CrossRef]Topchiy, E.; Cirstea, M.; Kong, H.; Boyd, J.; Wang, Y.; Russell, J.; Waley, K. Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor. PLoS ONE 2016, 11, e0155030. [CrossRef]Rohr, M.W.; Narasimhulu, C.; Rudeski-Rohr, T.; Parthasarathy, S. Negative Effects of a High-Fat Diet on Intestinal Permeability: A Review. Adv. Nutr. 2020, 11, 77–91. [CrossRef] [PubMed]Lam, Y.Y.; Ha, C.W.Y.; Hoffmann, J.M.A.; Oscarsson, J.; Dinudom, A.; Mather, T.J.; Cook, D.I.; Hunt, N.H.; Caterson, I.D.; Holmes, A.J.; et al. Effects of Dietary Fat Profile on Gut Permeability and Microbiota and Their Relationships with Metabolic Changes in Mice. Obesity 2015, 23, 1429–1439. [CrossRef] [PubMed]Guo, S.; Al-Sadi, R.; Said, H.M.; Ma, T.Y. Lipopolysaccharide Causes an Increase in Intestinal Tight Junction Permeability in Vitro and in Vivo by Inducing Enterocyte Membrane Expression and Localization of TLR-4 and CD14. Am. J. Pathol. 2013, 182, 375–387. [CrossRef] [PubMed]Guo, S.; Nighot, M.; Al-Sadi, R.; Alhmoud, T.; Nighot, P.; Ma, T.Y. Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88. J. Immunol. 2015, 195, 4999–5010. [CrossRef]Garidou, L.; Pomié, C.; Klopp, P.; Waget, A.; Charpentier, J.; Aloulou, M.; Giry, A.; Serino, M.; Stenman, L.; Lahtinen, S.; et al. The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORγt and Controls Metabolic Disease. Cell. Metab. 2015, 22, 100–112. [CrossRef]Cavallari, J.F.; Denou, E.; Foley, K.P.; Khan, W.I.; Schertzer, J.D. Different Th17 Immunity in Gut, Liver, and Adipose Tissues during Obesity: The Role of Diet, Genetics, and Microbes. Gut Microbes 2016, 7, 82–89. [CrossRef]Gomes, J.; de Assis, J.; Gonçalves, R. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism 2017, 86, 133–144. [CrossRef]Matheus, V.A.; Monteiro, L.; Oliveira, R.B.; Maschio, D.A.; Collares-Buzato, C.B. Butyrate Reduces High-Fat Diet-Induced Metabolic Alterations, Hepatic Steatosis and Pancreatic Beta Cell and Intestinal Barrier Dysfunctions in Prediabetic Mice. Exp. Biol. Med. 2017. [CrossRef]Pedersen, C.; Gallagher, E.; Horton, F.; Ellis, R.J.; Ijaz, U.Z.; Wu, H.; Jaiyeola, E.; Diribe, O.; Duparc, T.; Cani, P.D.; et al. Host–Microbiome Interactions in Human Type 2 Diabetes Following Prebiotic Fibre (Galacto-Oligosaccharide) Intake. Br. J. Nutr. 2016, 116, 1869–1877. [CrossRef]Song, M.J.; Kim, K.H.; Yoon, J.M.; Kim, J.B. Activation of Toll-like Receptor 4 Is Associated with Insulin Resistance in Adipocytes. Biochem. Biophys. Res. Commun. 2006, 346, 739–745. [CrossRef]Amyot, J.; Semache, M.; Ferdaoussi, M.; Fontés, G.; Poitout, V. Lipopolysaccharides Impair Insulin Gene Expression in Isolated Islets of Langerhans via Toll-Like Receptor-4 and NF-KB Signalling. PLoS ONE 2012, 7, e36200. [CrossRef] [PubMed]Cao, J.; Peng, J.; An, H.; He, Q.; Boronina, T.; Guo, S.; White, M.F.; Cole, P.A.; He, L. Endotoxemia-Mediated Activation of Acetyltransferase P300 Impairs Insulin Signaling in Obesity. Nat. Commun. 2017, 8, 131. [CrossRef] [PubMed]Kelder, T.; Stroeve, J.H.M.; Bijlsma, S.; Radonjic, M.; Roeselers, G. Correlation Network Analysis Reveals Relationships between Diet-Induced Changes in Human Gut Microbiota and Metabolic Health. Nutr. Diabetes 2014, 4, e122. [CrossRef] [PubMed]Mariat, D.; Firmesse, O.; Levenez, F.; Guimarăes, V.; Sokol, H.; Doré, J.; Corthier, G.; Furet, J.P. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009, 9, 123. [CrossRef]Sikalidis, A.; Maykish, A. The Gut Microbiome and Type 2 Diabetes Mellitus: Discussing a Complex Relationship. Biomedicines 2020, 8, 8. [CrossRef]Magne, F.; Gotteland, M.; Gauthier, L.; Zazueta, A.; Pesoa, S.; Navarrete, P.; Balamurugan, R. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients. Nutrients 2020, 12, 1474. [CrossRef]Larsen, N.; Vogensen, F.; Van den Berg, F.; Nielsen, D.S.; Andreasen, A.S.; Pedersen, B.K.; Al-Soud, W.A.; Sørensen, S.J.; Hansen, L.H.; Jakobsen, M. Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults. PLoS ONE 2010, 5, e9085. [CrossRef]Endesfelder, D.; Engel, M.; Davis-Richardson, A.G.; Ardissone, A.N.; Achenbach, P.; Hummel, S.; Winkler, C.; Atkinson, M.; Schatz, D.; Triplett, E.; et al. Towards a Functional Hypothesis Relating Anti-Islet Cell Autoimmunity to the Dietary Impact on Microbial Communities and Butyrate Production. Microbiome 2016, 4, 17. [CrossRef]Xu, J.; Lian, F.; Zhao, L.; Zhao, Y.; Chen, X.; Zhang, X.; Guo, Y.; Zhang, C.; Zgou, Q.; Xue, Z.; et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J. 2015, 9, 552–562. [CrossRef]Yanagibashi, T.; Hosono, A.; Oyama, A.; Tsuda, M.; Suzuki, A.; Hachimura, S.; Takahashi, Y.; Momose, Y.; Itoh, K.; Hirayama, K.; et al. IgA Production in the Large Intestine Is Modulated by a Different Mechanism than in the Small Intestine: Bacteroides Acidifaciens Promotes IgA Production in the Large Intestine by Inducing Germinal Center Formation and Increasing the Number of IgA+ B Cells. Immunobiology 2013, 218, 645–651. [CrossRef] [PubMed]Murri, M.; Leiva, I.; Gomez-Zumaquero, J.M.; Tinahones, F.J.; Cardona, F.; Soriguer, F.; Queipo-Ortuño, M.I. Gut Microbiota in Children with Type 1 Diabetes Differs from That in Healthy Children: A Case-Control Study. BMC Med. 2013, 11, 46. [CrossRef] [PubMed]Jandhyala, S.M.; Madhulika, A.; Deepika, G.; Rao, G.V.; Reddy, D.N.; Subramanyam, C.; Sasikala, M.; Talukdar, R. Altered Intestinal Microbiota in Patients with Chronic Pancreatitis: Implications in Diabetes and Metabolic Abnormalities. Sci. Rep. 2017, 7, 43640. [CrossRef] [PubMed]Remely, M.; Aumueller, E.; Merold, C.; Dworzak, S.; Hippe, B.; Zanner, J.; Pointner, A.; Brath, H.; Haslberger, A.G. Effects of Short Chain Fatty Acid Producing Bacteria on Epigenetic Regulation of FFAR3 in Type 2 Diabetes and Obesity. Gene 2014, 537, 85–92. [CrossRef]Gurung, M.; Li, Z.; You, H.; Rodrigues, R.; Jump, D.B.; Morgun, A.; Shulzhenko, N. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 2020, 51, 102590. [CrossRef]Kim, C.H. Microbiota or Short-Chain Fatty Acids: Which Regulates Diabetes. Cell. Mol. Immunol. 2018, 15, 88–91. [CrossRef]Puddu, A.; Sanguineti, R.; Montecucco, F.; Viviani, G.L. Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes. Mediat. Inflamm. 2014, 2014, 162021. [CrossRef]Myhrstad, M.C.W.; Tunsjø, H.; Charnock, C.; Telle-Hansen, V.H. Dietary Fiber, Gut Microbiota, and Metabolic Regulation-Current Status in Human Randomized Trials. Nutrients 2020, 12, 859. [CrossRef]Ratajczak, W.; Rył, A.; Mizerski, A.; Walczakiewicz, K.; Sipak, O.; Laszczy ´nska, M. Immunomodulatory Potential of Gut Microbiome-Derived Short-Chain Fatty Acids (SCFAs). Acta Biochim. Pol. 2019, 66, 1–12. [CrossRef]Kimura, I.; Ichimura, A.; Ohue-Kitano, R.; Igarashi, M. Free Fatty Acid Receptors in Health and Disease. Physiol. Rev. 2020, 100, 171–210. [CrossRef] [PubMed]Lee, S.U.; In, H.J.; Kwon, M.S.; Park, B.; Jo, M.; Kim, M.-O.; Cho, S.; Lee, S.; Lee, H.-J.; Kwak, Y.S.; et al. β-Arrestin 2 Mediates G Protein-Coupled Receptor 43 Signals to Nuclear Factor-KB. Biol. Pharm. Bull. 2013, 36, 1754–1759. [CrossRef] [PubMed]Cox, M.A.; Jackson, J.; Stanton, M.; Rojas-Triana, A.; Bober, L.; Laverty, M.; Yang, X.; Zhu, F.; Liu, J.; Wang, S.; et al. Short-Chain Fatty Acids Act as Antiinflammatory Mediators by Regulating Prostaglandin E(2) and Cytokines. World J. Gastroenterol. 2009, 15, 5549–5557. [CrossRef] [PubMed]Hernández, M.A.G.; Canfora, E.E.; Jocken, J.W.E.; Blaak, E.E. The Short-Chain Fatty Acid Acetate in Body Weight Control and Insulin Sensitivity. Nutrients 2019, 11, 1943. [CrossRef]Larasati, R.A.; Harbuwono, D.S.; Rahajeng, E.; Pradipta, S.; Nuraeni, H.S.; Susilowati, A.; Wibowo, H. The Role of Butyrate on Monocyte Migration and Inflammation Response in Patient with Type 2 Diabetes Mellitus. Biomedicines 2019, 7, 74. [CrossRef]Chun, E.; Lavoie, S.; Fonseca-Pereira, D.; Bae, S.; Michaud, M.; Hoveyda, H.R.; Fraser, G.L.; Gallini Comeau, C.A.; Glickman, J.N.; Fuller, M.H.; et al. Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity. Immunity 2019, 51, 871–884. [CrossRef]Wu, W.; Sun, M.; Chen, F.; Cao, A.T.; Liu, H.; Zhao, Y.; Huang, X.; Xiao, Y.; Yao, S.; Zhao, Q.; et al. Microbiota Metabolite Short-Chain Fatty Acid Acetate Promotes Intestinal IgA Response to Microbiota Which Is Mediated by GPR43. Mucosal. Immunol. 2017, 10, 946–956. [CrossRef]Kim, C.H.; Park, J.; Kim, M. Gut Microbiota-Derived Short-Chain Fatty Acids, T Cells, and Inflammation. Immune Netw. 2014, 14, 277–288. [CrossRef]Astakhova, L.; Ngara, M.; Babich, O.; Prosekov, A.; Asyakina, L.; Dyshlyuk, L.; Midtvedt, T.; Zhou, X.; Ernberg, I.; Matskova, L. Short Chain Fatty Acids (SCFA) Reprogram Gene Expression in Human Malignant Epithelial and Lymphoid Cells. PLoS ONE 2016, 11, e0154102. [CrossRef]Yap, Y.A.; Mariño, E. Dietary SCFAs Immunotherapy: Reshaping the Gut Microbiota in Diabetes. In SpringerLink; Springer: New York, NY, USA, 2020. [CrossRef]Mariño, E.; Richards, J.L.; McLeod, K.H.; Stanley, D.; Yap, Y.A.; Knight, J.; McKenzie, C.; Kranich, J.; Oliveira, A.C.; Rossello, F.J.; et al. Gut Microbial Metabolites Limit the Frequency of Autoimmune T Cells and Protect against Type 1 Diabetes. Nat. Immunol. 2017, 18, 552–562. [CrossRef]Rahat-Rozenbloom, S.; Fernandes, J.; Cheng, J.; Wolever, T.M.S. Acute Increases in Serum Colonic Short-Chain Fatty Acids Elicited by Inulin Do Not Increase GLP-1 or PYY Responses but May Reduce Ghrelin in Lean and Overweight Humans. Eur. J. Clin. Nutr. 2017, 71, 953–958. [CrossRef] [PubMed]Bjerg, A.T.; Kristensen, M.; Ritz, C.; Holst, J.J.; Rasmussen, C.; Leser, T.D.; Wellejus, A.; Astrup, A. Lactobacillus Paracasei Subsp Paracasei L. Casei W8 Suppresses Energy Intake Acutely. Appetite 2014, 82, 111–118. [CrossRef] [PubMed]De Velasco, P.; Ferreira, A.; Crovesy, L.; Marine, T.; Das Graças Tavares do Carmo, M. Fatty Acids, Gut Microbiota, and the Genesis of Obesity. In Biochemistry and Health Benefits of Fatty Acids; Waisundara, V., Ed.; IntechOpen: London, UK, 2018.Grasset, E.; Puel, A.; Charpentier, J.; Collet, X.; Christensen, J.E.; Tercé, F.; Burcelin, R. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab. 2017, 25, 1075–1090. [CrossRef] [PubMed]Perry, R.J.; Peng, L.; Barry, N.A.; Cline, G.W.; Zhang, D.; Cardone, R.L.; Petersen, K.F.; Kibbey, R.G.; Goodman, A.L.; Shulman, G.I. Acetate Mediates a Microbiome–Brain–β-Cell Axis to Promote Metabolic Syndrome. Nature 2016, 534, 213–217. [CrossRef]Yang, M.; Wang, J.; Wu, S.; Yuan, L.; Zhao, X.; Liu, C.; Xie, J.; Jia, Y.; Lai, Y.; Zhao, A.Z.; et al. Duodenal GLP-1 Signaling Regulates Hepatic Glucose Production through a PKC-δ-Dependent Neurocircuitry. Cell Death Dis. 2017, 8, e2609. [CrossRef]Vieira, A.T.; Fukumori, C.; Ferreira, C.M. New Insights into Therapeutic Strategies for Gut Microbiota Modulation in Inflammatory Diseases. Clin. Transl. Immunol. 2016, 5, e87. [CrossRef]Kellow, N.J.; Coughlan, M.T.; Savige, G.S.; Reid, C.M. Effect of Dietary Prebiotic Supplementation on Advanced Glycation, Insulin Resistance and Inflammatory Biomarkers in Adults with Pre-Diabetes: A Study Protocol for a Double-Blind Placebo-Controlled Randomised Crossover Clinical Trial. BMC Endocr. Disord. 2014, 14, 55. [CrossRef]Kassaian, N.; Aminorroaya, A.; Feizi, A.; Jafari, P.; Amini, M. The Effects of Probiotic and Synbiotic Supplementation on Metabolic Syndrome Indices in Adults at Risk of Type 2 Diabetes: Study Protocol for a Randomized Controlled Trial. Trials 2017, 18, 148. [CrossRef]Yao, K.; Zeng, L.; He, Q.; Wang, W.; Lei, J.; Zou, X. Effect of Probiotics on Glucose and Lipid Metabolism in Type 2 Diabetes Mellitus: A Meta-Analysis of 12 Randomized Controlled Trials. Med. Sci. Monit. 2017, 23, 3044–3053. [CrossRef] [PubMed]Naito, E.; Yoshida, Y.; Makino, K.; Kounoshi, Y.; Kunihiro, S.; Takahashi, R.; Matsuzaki, T.; Miyazaki, K.; Ishikawa, F. Beneficial Effect of Oral Administration of Lactobacillus Casei Strain Shirota on Insulin Resistance in Diet-Induced Obesity Mice. J. Appl. Microbiol. 2011, 110, 650–657. [CrossRef] [PubMed]Chen, J.J.; Wang, R.; Li, X.; Wang, R. Bifidobacterium Longum Supplementation Improved High-Fat-Fed-Induced Metabolic Syndrome and Promoted Intestinal Reg I Gene Expression. Exp. Biol. Med. 2011, 236, 823–831. [CrossRef] [PubMed]Alfa, M.J.; Strang, D.; Tappia, P.S.; Olson, N.; De Gagne, P.; Bray, D.; Murray, B.-L.; Hiebert, B. A Randomized Placebo Controlled Clinical Trial to Determine the Impact of Digestion Resistant Starch MSPrebiotic® on Glucose, Insulin, and Insulin Resistance in Elderly and Mid-Age Adults. Front. Med. 2017, 4, 260. [CrossRef] [PubMed]De Vadder, F.; Kovatcheva-Datchary, P.; Goncalves, D.; Vinera, J.; Zitoun, C.; Duchampt, A.; Bäckhed, F.; Mithieux, G. Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits. Cell 2014, 156, 84–96. [CrossRef] [PubMed]Zheng, J.; Yuan, X.; Cheng, G.; Jiao, S.; Feng, C.; Zhao, X.; Yin, H.; Du, Y.; Liu, H. Chitosan Oligosaccharides Improve the Disturbance in Glucose Metabolism and Reverse the Dysbiosis of Gut Microbiota in Diabetic Mice. Carbohydr. Polym. 2018, 190, 77–86. [CrossRef] [PubMed]Chan, C.; Hyslop, C.M.; Shrivastava, V.; Ochoa, A.; Reimer, R.A.; Huang, C. Oligofructose as an Adjunct in Treatment of Diabetes in NOD Mice. Sci. Rep. 2016, 6, 37627. [CrossRef]Everard, A.; Matamoros, S.; Geurts, L.; Delzenne, N.M.; Cani, P.D. Saccharomyces Boulardii Administration Changes Gut Microbiota and Reduces Hepatic Steatosis, Low-Grade Inflammation, and Fat Mass in Obese and Type 2 Diabetic Db/Db Mice. MBio 2014, 5, e01011. [CrossRef]Karczewski, J.; Troost, F.J.; Konings, I.; Dekker, J.; Kleerebezem, M.; Brummer, R.-J.M.; Wells, J.M. Regulation of Human Epithelial Tight Junction Proteins by Lactobacillus Plantarum in Vivo and Protective Effects on the Epithelial Barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G851–G859. [CrossRef]Sharma, P.; Bhardwaj, P.; Singh, R. Administration of Lactobacillus Casei and Bifidobacterium Bifidum Ameliorated Hyperglycemia, Dyslipidemia, and Oxidative Stress in Diabetic Rats. Int. J. Prev. Med. 2016, 7. [CrossRef]Valladares, R.; Sankar, D.; Li, N.; Williams, E.; Lai, K.-K.; Abdelgeliel, A.S.; Gonzalez, C.F.; Wasserfall, C.H.; Iii, J.L.; Schatz, D.; et al. Lactobacillus Johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats. PLoS ONE 2010, 5, e10507. [CrossRef] [PubMed]Balakumar, M.; Prabhu, D.; Sathishkumar, C.; Prabu, P.; Rokana, N.; Kumar, R.; Raghavan, S.; Soundarajan, A.; Grover, S.; Batish, V.K.; et al. Improvement in Glucose Tolerance and Insulin Sensitivity by Probiotic Strains of Indian Gut Origin in High-Fat Diet-Fed C57BL/6J Mice. Eur. J. Nutr. 2016, 57, 279–295. [CrossRef] [PubMed]Yadav, H.; Lee, J.-H.; Lloyd, J.; Walter, P.; Rane, S.G. Beneficial Metabolic Effects of a Probiotic via Butyrate-Induced GLP-1 Hormone Secretion. J. Biol. Chem. 2013, 288, 25088–25097. [CrossRef] [PubMed]Asemi, Z.; Khorrami-Rad, A.; Alizadeh, S.-A.; Shakeri, H.; Esmaillzadeh, A. Effects of Synbiotic Food Consumption on Metabolic Status of Diabetic Patients: A Double-Blind Randomized Cross-over Controlled Clinical Trial. Clin. Nutr. 2014, 33, 198–203. [CrossRef] [PubMed]Ebrahimi, Z.S.; Nasli-Esfahani, E.; Nadjarzade, A.; Mozaffari-Khosravi, H. Effect of Symbiotic Supplementation on Glycemic Control, Lipid Profiles and Microalbuminuria in Patients with Non-Obese Type 2 Diabetes: A Randomized, Double-Blind, Clinical Trial. J. Diabetes Metab. Disord. 2017, 16, 23. [CrossRef] [PubMed]Shen, T.-C.D. Diet and Gut Microbiota in Health and Disease. In Intestinal Microbiome: Functional Aspects in Health and Disease; Nestlé Nutrition Institute Workshop Series; Karger Publishers: Basel, Switzerland, 2017; Volume 88, pp. 117–126. [CrossRef]Heianza, Y.; Sun, D.; Li, X.; DiDonato, J.A.; Bray, G.A.; Sacks, F.M.; Qi, L. Gut Microbiota Metabolites, Amino Acid Metabolites and Improvements in Insulin Sensitivity and Glucose Metabolism: The POUNDS Lost Trial. Gut 2018, 67. [CrossRef]Miranda, P.J.P.; Cueva, C. Rol de la metformina en el tratamiento de la diabetes mellitus gestacional: Situación actual. Arch. Venez. Farmacol. Ter. 2019, 38, 234–239.Napolitano, A.; Miller, S.; Nicholls, A.W.; Baker, D.; Van Horn, S.; Thomas, E.; Rajpal, D.; Spivak, A.; Brown, J.R.; Nunez, D.J. Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus. PLoS ONE 2014, 9, e100778. [CrossRef]Ridlon, J.M.; Harris, S.C.; Bhowmik, S.; Kang, D.-J.; Hylemon, P.B. Consequences of Bile Salt Biotransformations by Intestinal Bacteria. Gut Microbes 2016, 7, 22–39. [CrossRef]Forslund, K.; Hildebrand, F.; Nielsen, T.; Falony, G.; Le Chatelier, E.; Sunagawa, S.; Prifti, E.; Vieira-Silva, S.; Gudmundsdottir, V.; Krogh Pedersen, H.; et al. Disentangling Type 2 Diabetes and Metformin Treatment Signatures in the Human Gut Microbiota. Nature 2015, 528, 262–266. [CrossRef] [PubMed]De La Cuesta-Zuluaga, J.; Mueller, N.T.; Corrales-Agudelo, V.; Velásquez-Mejía, E.P.; Carmona, J.A.; Abad, J.M.; Escobar, J.S. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia Muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut. Diabetes Care 2016, dc161324. [CrossRef]Wu, H.; Esteve, E.; Tremaroli, V.; Khan, M.T.; Caesar, R.; Mannerås-Holm, L.; Ståhlman, M.; Olsson, L.M.; Serino, M.; Planas-Fèlix, M.; et al. Metformin Alters the Gut Microbiome of Individuals with Treatment-Naive Type 2 Diabetes, Contributing to the Therapeutic Effects of the Drug. Nat. Med. 2017, 23, 850–858. [CrossRef] [PubMed]Lee, H.; Ko, G. Effect of Metformin on Metabolic Improvement and Gut Microbiota. Appl. Environ. Microbiol. 2014, 80, 5935–5943. [CrossRef]Vallianou, N.; Stratigou, T.; Tsagarakis, S. Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones (Athens) 2019, 2, 141–144. [CrossRef]Bryrup, T.; Thomsen, C.W.; Kern, T.; Allin, K.H.; Brandslund, I.; Jørgensen, N.R.; Vestergaard, H.; Hansen, T.; Hansen, T.H.; Pedersen, O.; et al. Metformin-Induced Changes of the Gut Microbiota in Healthy Young Men: Results of a Non-Blinded, One-Armed Intervention Study. Diabetologia 2019, 62, 1024–1035. [CrossRef]Su, B.; Liu, H.; Li, J.; Sunli, Y.; Liu, B.; Liu, D.; Zhang, P.; Meng, X. Acarbose Treatment Affects the Serum Levels of Inflammatory Cytokines and the Gut Content of Bifidobacteria in Chinese Patients with Type 2 Diabetes Mellitus. J. Diabetes 2015, 7, 729–739. [CrossRef]Gu, Y.; Wang, X.; Li, J.; Zhang, Y.; Zhong, H.; Liu, R.; Zhang, D.; Feng, Q.; Xie, X.; Hong, J.; et al. Analyses of Gut Microbiota and Plasma Bile Acids Enable Stratification of Patients for Antidiabetic Treatment. Nat. Commun. 2017, 8, 1785. [CrossRef]Smith, B.J.; Miller, R.A.; Ericsson, A.C.; Harrison, D.C.; Strong, R.; Schmidt, T.M. Changes in the Gut Microbiome and Fermentation Products Concurrent with Enhanced Longevity in Acarbose-Treated Mice. BMC Microbiol. 2019, 19, 130. [CrossRef]Baxter, N.T.; Lesniak, N.A.; Sinani, H.; Schloss, P.D.; Koropatkin, N.M. The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome. MSphere 2019, 4. [CrossRef]Zhao, L.; Chen, Y.; Xia, F.; Abudukerimu, B.; Zhang, W.; Guo, Y.; Wang, N.; Lu, Y. A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front. Endocrinol. 2018, 9, 233. [CrossRef] [PubMed]Wang, L.; Li, P.; Tang, Z.; Yan, X.; Feng, B. Structural Modulation of the Gut Microbiota and the Relationship with Body Weight: Compared Evaluation of Liraglutide and Saxagliptin Treatment. Sci. Rep. 2016, 6, 33251. [CrossRef] [PubMed]Wang, Z.; Saha, S.; Van Horn, S.; Thomas, E.; Traini, C.; Sathe, G.; Rajpal, D.K.; Brown, J.R. Gut Microbiome Differences between Metformin- and Liraglutide-Treated T2DM Subjects. Endocrinol. Diabetes Metab. 2018, 1, e00009. [CrossRef] [PubMed]Sun, L.; Xie, C.; Wang, G.; Wu, Y.; Wu, Q.; Wang, X.; Liu, J.; Deng, Y.; Xia, J.; Chen, B.; et al. Gut Microbiota and Intestinal FXR Mediate the Clinical Benefits of Metformin. Nat. Med. 2018, 24, 1919–1929. [CrossRef]Fang, S.; Suh, J.M.; Reilly, S.M.; Yu, E.; Osborn, O.; Lackey, D.; Yoshihara, E.; Perino, A.; Jacinto, S.; Lukasheva, Y.; et al. Intestinal FXR Agonism Promotes Adipose Tissue Browning and Reduces Obesity and Insulin Resistance. Nat. Med. 2015, 21, 159–165. [CrossRef]Pathak, P.; Xie, C.; Nichols, R.G.; Ferrell, J.M.; Boehme, S.; Krausz, K.W.; Patterson, A.D.; Gonzalez, F.J.; Chiang, J.Y.L. Intestine Farnesoid X Receptor Agonist and the Gut Microbiota Activate G-Protein Bile Acid Receptor-1 Signaling to Improve Metabolism. Hepatology 2018, 68, 1574–1588. [CrossRef]Zhang, X.; Fang, Z.; Zhang, C.; Xia, H.; Jie, Z.; Han, X.; Chen, Y.; Ji, L. Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-Blind, Controlled Crossover Trial. Diabetes Ther. 2017, 8, 293–307. [CrossRef]Remely, M.; Hippe, B.; Zanner, J.; Aumueller, E.; Brath, H.; Haslberger, A.G. Gut Microbiota of Obese, Type 2 Diabetic Individuals Is Enriched in Faecalibacterium Prausnitzii, Akkermansia Muciniphila and Peptostreptococcus Anaerobius after Weight Loss. Endocr. Metab. Immune Disord. Drug Targets 2016, 16, 99–106. [CrossRef]Xu, G.-D.; Cai, L.; Ni, Y.-S.; Tian, S.-Y.; Lu, Y.-Q.; Wang, L.-N.; Chen, L.-L.; Ma, W.-Y.; Deng, S.-P. Comparisons of Effects on Intestinal Short-Chain Fatty Acid Concentration after Exposure of Two Glycosidase Inhibitors in Mice. Biol. Pharm. Bull. 2018, 41, 1024–1033. [CrossRef]Zhang, Q.; Xiao, X.; Zheng, J.; Li, M.; Yu, M.; Ping, F.; Wang, T.; Wang, X. Featured Article: Structure Moderation of Gut Microbiota in Liraglutide-Treated Diabetic Male Rats. Exp. Biol. Med. 2018, 243, 34–44. [CrossRef] [PubMed]ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf2176241https://bonga.unisimon.edu.co/bitstreams/ae3e9a76-f10f-4c99-aa8e-76fbf1a9efc5/download1de51755447e8f231fc7158108f84bb8MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/949d02f8-57bb-472a-acf7-b2bf4a3f3649/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/949e5701-d0c7-478f-ab64-79723322e1a2/download733bec43a0bf5ade4d97db708e29b185MD53TEXTMicrobiota_and_Diabetes_Mellitus.pdf.txtMicrobiota_and_Diabetes_Mellitus.pdf.txtExtracted texttext/plain83992https://bonga.unisimon.edu.co/bitstreams/f54f0da2-588a-4e67-ab16-a4e1b93b3579/download54cc2d13a02f199db14efea76b3d10fbMD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain93338https://bonga.unisimon.edu.co/bitstreams/c74ba7fc-160e-4324-ab12-464860b0906a/downloadb6458a6972d91144fe1004934b1f3381MD56THUMBNAILMicrobiota_and_Diabetes_Mellitus.pdf.jpgMicrobiota_and_Diabetes_Mellitus.pdf.jpgGenerated Thumbnailimage/jpeg1614https://bonga.unisimon.edu.co/bitstreams/0dde2498-e38f-4976-8fd1-2caf4ec638e6/download21a04d2bd9aa4a8a41c188fff68f3e13MD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5295https://bonga.unisimon.edu.co/bitstreams/41a55f46-e53d-433b-a93a-5a6286e3ae16/download97e47bfe5014a0ab6a7ad96f39202e30MD5720.500.12442/7003oai:bonga.unisimon.edu.co:20.500.12442/70032024-08-14 21:51:32.545http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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 |